Acuitas Sues Partner CureVac for Vaccine-Tech Patents Share (1)

Acuitas Therapeutics Inc. injected itself into a clash over vaccine-delivery technology involving three of its collaborators, suing CureVac NV to gain partial control of patents central to a blockbuster Covid-19 shot.

Vancouver-based Acuitas wants four of its scientists—including a co-founder—added as inventors to patents that CureVac in a pending case alleges are infringed by BioNTech SE and Pfizer Inc.'s Comirnaty vaccine. Acuitas also asked the US District Court for the Eastern District of Virginia to let it wade into the separate suit over claims linked to the disputed patents, whose inventorship Acuitas wants corrected.

The company would be “irretrievably harmed” ...